Liraglutide: another reason to target prediabetes?

Abstract

Glucagon-like peptide-1 (GLP-1) analogues, such as liraglutide, reduce bodyweight regardless of glycaemic status [1, 2], and are effective treatments for type 2 diabetes [3]. The anti-diabetic mechanism of action is based on enhancement of glucose-dependent insulin secretion, and an additional insulin sensitising effect characterised by weight loss and… (More)
DOI: 10.18632/oncotarget.22256

Topics

Cite this paper

@inproceedings{Murphy2017LiraglutideAR, title={Liraglutide: another reason to target prediabetes?}, author={Conor F. Murphy and Neil G Docherty and Carel Wynard le Roux}, booktitle={Oncotarget}, year={2017} }